CD146 - Journal of Biological Chemistry

THE JOURNAL OF BIOLOGICAL CHEMISTRY © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

Vol. 273, No. 41, Issue of October 9, pp. 26852–26856, 1998 Printed in U.S.A.

Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125FAK* (Received for publication, May 1, 1998, and in revised form, July 17, 1998)

Francine Anfosso‡, Nathalie Bardin, Ve´ronique France`s, Eric Vivier§, Laurence Camoin-Jau, Jose´ Sampol, and Franc¸oise Dignat-George From the Laboratoire d’He´matologie-Immunologie, Unite´ de Formation et de Recherche Pharmacie, 13385 Marseille, and the §Centre d’Immunologie INSERM-CNRS, Marseille Luminy and the Institut Universitaire de France, 13288 Marseille, France

S-Endo-1 antigen (CD146) is an integral membrane protein present on human endothelial cells. It is identical to MUC18/ MCAM, an antigen found on melanoma cells. CD146 is ubiquitously present on the endothelium along the whole vascular tree and is highly expressed on human umbilical vein endothelial cells (HUVECs)1 (1, 2). CD146 expression is not restricted to the endothelium; it is also detected in nonmalignant and malignant cells from other tissues (3–7). CD146 (113–119 kDa) is a highly glycosylated monomer that belongs to the immunoglobulin (Ig) superfamily of cell adhesion molecules (1, 8, 9). CD146 contains five extracellular Ig-like homology domains (V-V-C2-C2-C2), one transmembrane segment, and a short cytoplasmic tail (10). CD146 molecular cloning has revealed significant homology to other Ig superfamily

* This work was supported by Grant UPRES EA 2195 from the Ministe`re de l’Education Nationale. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ‡ To whom correspondence should be addressed: Laboratoire d’He´matologie-Immunologie, UFR Pharmacie 27, Bd Jean Moulin, 13385 Marseille cedex 5, France. Tel.: 33-4-9183-5600; Fax: 33-4-91835602; E-mail: [email protected]. 1 The abbreviations used are: HUVEC, human umbilical vein endothelial cell; mAb, monoclonal antibody; Tyr(P), phosphotyrosine; antiTyr(P) mAb, mouse monoclonal antibody against phosphotyrosine; GAMIg, goat anti-mouse immunoglobulin; NaV, peroxovanadate; PAGE, polyacrylamide gel electrophoresis; PTK, protein tyrosine kinase; C, constant; V, variable.

adhesion molecules such as B-CAM, ALCAM, BEN/DMGRASP/SC1, KG-CAM, the chicken HEMCAM, and gicerin (11–16). CD146 function is still not elucidated, although recent data suggest its involvement in cell-cell adhesion. Indeed, the expression of CD146 on melanoma cells correlates with an invasive phenotype, indicating that CD146 may be used as a cell surface marker of tumor progression and metastasis formation (17–19). Indeed, CD146 has been shown to be involved in tumor-endothelial cell interactions that might lead to extravasation of tumor cells (20, 21). Finally, it has been reported that CD146 mediates a Ca21-independent homotypic melanoma cell adhesion by promoting heterophilic interaction through a still unknown ligand (19, 21). CD146 is located at the interendothelial junctions. It is found in cytoskeletal protein-rich fractions and colocalizes with a-actinin (22).2 It is well documented that proteins present at the interendothelial junctions promote adhesion through their extracellular domain and mediate intracellular signaling to the complex network of cytoskeletal proteins through their intracytoplasmic part (23). CD146 possesses potential recognition sites for protein kinases in its cytoplasmic tail (9) which might be involved in signal transduction. Nevertheless, CD146 involvement in outside-in signaling in HUVECs has not been investigated. In this present report, we investigated the signaling pathways initiated by CD146 engagement. Because the ligand of CD146 is unknown, CD146 clustering was performed using anti-CD146 monoclonal antibody (mAb) on HUVECs. Results indicate that cross-linking of CD146 induces tyrosine phosphorylation of a large panel of proteins, among which p125FAK and paxillin associate with each other. However, CD146 is not directly bound to these proteins but becomes associated with p59 fyn. Thus, our results indicate that CD146 engagement may initiate a reorganization of the cytoskeleton through a p59 fynand p125FAK-dependent pathway. EXPERIMENTAL PROCEDURES

Antibodies—The following mAbs and polyclonal antibodies were used: S-Endo-1 (F(ab9)2 fragment) and 7A4 mAbs, both specific for CD146 and kindly given by Biocytex (Marseilles, France); anti-Tyr(P) 4G10 (Upstate Biotechnology, Lake Placid, NY) and PY20 (Transduction Laboratories, Lexington, KY) mAbs; anti-p125FAK, anti-paxillin, anti-p53/56lyn, p59 fyn mAbs (Transduction Laboratories); rabbit antip72syk (kindly given by Dr. R. Geahlen, IN); isotype-matched IgG1 or IgG2a (Sigma, St. Louis, MO); horseradish peroxidase-labeled goat anti-rabbit, goat anti-mouse (GAMIg) and its F(ab9)2 fragment (Jackson laboratories, Palo Alto, CA). 2 N. Bardin, V. France`s, J. Sampol, and F. Dignat-George, manuscript in preparation.

26852

This paper is available on line at http://www.jbc.org

Downloaded from http://www.jbc.org/ by guest on November 27, 2017

S-Endo-1 antigen (CD146), a transmembrane receptor also known as MUC18/MCAM, is a member of the immunoglobulin superfamily and belongs to a group of cell adhesion molecules. CD146 is highly expressed on the whole vascular tree. We demonstrate here that engagement of CD146 on human endothelial cells isolated from cord blood results in tyrosine phosphorylation of a large panel of cellular proteins, although no tyrosine phosphorylation of CD146 was detected. In particular, CD146 cross-linking induces the tyrosine phosphorylation of the protein tyrosine kinase p125FAK as well as p125FAK association with paxillin, both events being inhibited by cytochalasin D. No direct association of CD146 with p125FAK was observed. Consistent with these data, CD146 associates with p59 fyn, a Src family kinase known to phosphorylate p125FAK. The identification of a signaling pathway initiated by CD146 engagement and which includes p59 fyn, p125FAK, and paxillin indicates that CD146 participates in outside-in signaling in endothelial cells.

CD146 Engagement Initiates a PTK-dependent Signaling Pathway

26853

Cell Culture—HUVECs were isolated from cord blood (24). They were used at confluence after one passage. They were rendered quiescent by incubation in RPMI 1640 medium containing 1% fetal calf serum 2 h before cell activation. Cell Activation and Inhibitor Treatment—Quiescent HUVECs were incubated in Hanks’ balanced salt solution for 30 min at 4 °C with either isotype-matched IgG1 (control cells) or 10 mg/ml S-Endo-1 F(ab9)2 mAb for CD146 clustering; when indicated, cells were further stimulated with 20 mg/ml F(ab9)2 GAMIg for 30 min at 37 °C. After three washes at 4 °C, the cells were lysed for immunoblotting. Genistein, Herbimycin, and Cytochalasin D (Alexis, San Diego, CA) were used at 50, 10, and 5 mM, respectively. HUVECs were incubated with the drugs in serum-free Hanks’ balanced salt solution 1 h before the clustering of CD146 with S-Endo-1 mAb. Peroxovanadate (NaV) was generated as described previously (25). HUVECs were incubated in presence of a 100 mM NaV solution for up to 15 min. Immunoprecipitation—After activation, the cells were lysed at 4 °C in 500 ml of lysis buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 2 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride, 25 mg/ml aprotinin, 2 mg/ml leupeptin, 2 mg/ml pepstatin). After adjustment to a protein concentration of 300 –500 mg, i.e. 3– 6 3 106 cells (bicinchoninic acid assay, Pierce, Rockford, IL), cell lysates were precleared by incubation with irrelevant IgG1 or IgG2a mAbs and protein G-Sepharose (Pharmacia Biotech, Uppsala, Sweden) for 1 h at 4 °C. Precleared samples were immunoprecipitated with 2 mg for 3 h at 4 °C followed by a 2-h incubation with protein G-Sepharose. Immunoprecipitates were analyzed by SDS-PAGE and immunoblotting. Immunoprecipitations using anti-CD146 and anti-Tyr(P) were performed, respectively, with S-Endo-1 and 4G10 mAbs. Immunoblotting—Immunoprecipitates or total cell lysates were subjected to SDS-PAGE and transferred to nitrocellulose C1 filters. After blocking in 10 mM Tris-HCl buffer, pH 7.5, 0.15 M NaCl, 0.1% Tween 20, 3% bovine serum albumin (TBS-T BSA), they were incubated in TBS-T BSA containing protein-specific antibodies (1 mg/ml) for 1 h at room temperature. Immunoreactive bands were visualized by chemilumines-

FIG. 2. CD146 is not a tyrosine-phosphorylated protein. HUVECs were either activated by CD146 engagement or incubated with 0.1 mM NaV, as described under “Experimental Procedures.” Lysates (300 mg) were immunoprecipitated (IP) using S-Endo-1 or 4G10 mAbs, separated on 7% SDS-PAGE, and immunoblotted (WB) using 7A4 or PY20 mAbs as indicated (upper panel). Blots were then stripped and reblotted with 7A4 mAb (lower panel). C indicates IgG1 isotypematched control cells. cence using horseradish peroxidase-conjugated anti-mouse or rabbit IgG and ECL reagent. Western blotting using anti-CD146 was performed with 7A4 mAb. When required, membranes were stripped in 62.5 mM Tris-HCl, pH 6.8, 2 mM EDTA, 2% SDS, 100 mM b-mercaptoethanol for 30 min at 60 °C and reblotted with the indicated antibodies. RESULTS

CD146 Engagement Induces a Pattern of Tyrosine-phosphorylated Proteins in HUVECs—Engagement of CD146 was obtained by incubating HUVECs with S-Endo-1 F(ab9)2 mAb and subsequently by cross-linking the complexes with GAMIg. Whole cell lysates were analyzed on a 5–15% gradient SDSPAGE followed by immunoblotting with anti-Tyr(P) mAb. In HUVECs, engagement of CD146 induced the tyrosine phosphorylation of a large panel of proteins (Fig. 1, lane 2), which was increased further upon cross-linking with GAMIg at 37 °C for 30 min (Fig. 1, lane 3). The complex pattern of tyrosine-phosphorylated proteins consistently includes proteins at apparent molecular masses of 46, 55– 60, 70 – 80, 100, 125, and 150 kDa. A 2-h pretreatment of HUVEC with 50 mM genistein (Fig. 1,


FIG. 1. Induction of tyrosine phosphorylation by CD146 engagement in HUVECs. HUVECs were treated by S-Endo-1 (F(ab9)2) mAb fragment alone or cross-linked with GAMIg as described under “Experimental Procedures.” Genistein (50 mM) or herbimycin (2 mM) was added 2 h before cell activation. After cell lysing, 50 mg of proteins was analyzed on a linear 5–15% gradient SDS-PAGE. Immunoblotting was performed with PY20 anti-Tyr(P). The position of prestained standards and their molecular masses in kDa are indicated. C indicates IgG1 isotype-matched control cells. Results are representative of five independent experiments.

26854


lane 4) or 2 mM herbimycin (Fig. 1, lane 5) greatly reduced the tyrosine phosphorylation induced by CD146 engagement. Kinetic analysis of the induction of tyrosine phosphorylation upon CD146 engagement revealed a rapid onset after 5 min, a maximum at 30 min, followed by a decrease thereafter (data not shown). In contrast, in HUVECs treated with a control isotypematched (IgG1) antibody cross-linked with GAMIg, a pattern of constitutive tyrosine phosphorylation was barely detectable (Fig. 1, lane 1). CD146 Clustering Did Not Induce CD146 Phosphorylation— The presence of a tyrosine residue at position 641 (Tyr-Ile-AspLeu) in CD146 cytoplasmic tail suggests a potential site of phosphorylation of the molecule (9). The capacity of CD146 engagement to phosphorylate Tyr641 was studied. As shown in Fig. 2 (upper panel), anti-Tyr(P) immunoblotting of anti-CD146 immunoprecipitation revealed that CD146 is not tyrosine-phosphorylated, either in isotype-matched control (lane 1) or in CD146-stimulated cells (lane 2). Reciprocal experiments, using anti-CD146 immunoblotting of anti-Tyr(P) immunoprecipitation, led to similar results (Fig. 2, upper panel, lane 4). As a control, immunoprecipitation and immunoblotting with antiCD146 mAbs revealed the presence of CD146 in these samples (Fig. 2, lower panel). NaV is a potent inducer of tyrosine phosphorylation (25) and was tested for its ability to promote tyrosine phosphorylation of CD146. HUVECs were treated with 0.1 mM NaV for 15 min and lysed. No tyrosine phosphorylation in the molecular weight range of CD146 was observed in anti-Tyr(P) immunoblots of anti-CD146 immunoprecipitates (Fig. 2, lane 3), although CD146 was present in the cell lysate after reblotting. The lack of tyrosine phosphorylation in CD146 was observed irrespec-

tive of the dose of NaV (0.2–3 mM) and time of incubation (2–30 min) used in the experiments (data not shown). CD146 Engagement Induces Tyrosine Phosphorylation of p125FAK and Paxillin—The colocalization of CD146 with cytoskeletal proteins2 and the tyrosine phosphorylation of a band in the molecular weight range of 125,000 suggested that p125FAK could be tyrosine-phosphorylated upon CD146 engagement (26). To examine whether CD146 engagement stimulates tyrosine phosphorylation of p125FAK in HUVECs, cell lysates were immunoprecipitated with anti-p125FAK mAb and immunoblotted with anti-Tyr(P) mAb. Fig. 3A shows that a constitutive tyrosine phosphorylation of p125FAK occurs in isotype-matched control cells (lane 1). CD146 engagement caused a marked increase in the tyrosine phosphorylation of p125FAK (Fig. 3A, lane 2). Disruption of the actin network by a 2-h pretreatment of the HUVEC monolayer with 5 mM cytochalasin D inhibited the p125FAK tyrosine phosphorylation mediated by CD146 clustering (Fig. 3A, lane 3). A direct association between CD146 and p125FAK was investigated in response to CD146 engagement. Cell lysates were immunoprecipitated with anti-CD146 and immunoblotted with anti-p125FAK. No protein in the molecular mass range of '125 kDa was detected (Fig. 3B, upper panel), although reprobing with anti-CD146 mAb indicated that CD146 was present in anti-CD146 immunoprecipitates (Fig. 3B, lower panel). These results showed that CD146 cross-linking induces p125FAK phosphorylation but does not induce an association between CD146 and p125FAK. Tyrosine phosphorylation of paxillin, a substrate for p125FAK (27), and its association with p125FAK were investigated in response to CD146 engagement. Results in Fig. 3C indicate


FIG. 3. CD146 engagement stimulates p125FAK tyrosine phosphorylation and paxillin association to p125FAK in HUVECs. CD146 engagement was performed as described under “Experimental Procedures.” Lysates (300 mg) were immunoprecipitated, separated on 7% SDS-PAGE, and immunoblotted as indicated. C indicates IgG1 isotype-matched control cells. Panel A, tyrosine phosphorylation of p125FAK induced by CD146 engagement in absence or after pretreatment with 5 mM cytochalasin D. Panel B, lack of association of p125FAK with CD146. Lysates were immunoprecipitated using S-Endo-1 and immunoblotted with anti-FAK mAbs (upper panel). Blots were then stripped and reblotted with 7A4 mAb (lower panel). Panel C, tyrosine phosphorylation of paxillin and its association with p125FAK.


26855

FIG. 4. Association of CD146 with p59 fyn. CD146 engagement was performed as described under “Experimental Procedures.” Lysates (500 mg) were immunoprecipitated using S-Endo-1 mAb. Immunoprecipitates were first immunoblotted with the indicated anti-PTK antibodies (upper panel) and reblotted with 7A4 mAb (lower panel).

DISCUSSION

The results reported here demonstrate that in cultured HUVECs, engagement of CD146 initiates a PTK-dependent signaling cascade. Activation of this pathway results in the tyro-

sine phosphorylation of a complex pattern of proteins, including p125FAK and paxillin as well as the association of p59 fyn with CD146. To our knowledge, this is the first report demonstrating an outside-in signaling pathway downstream of CD146. Dimerization of cell surface receptors represents a key event in signal transduction (28). Binding of S-Endo-1 mAb to the extracellular part of CD146 induces a dimerization of CD146 sufficient to promote the tyrosine phosphorylation of intracellular proteins. Cross-linking of CD146 dimers by a secondary antibody leads to an oligomerization of CD146 which subsequently increases the intensity of the phosphorylation events. This process is time- and dose-dependent and requires genistein- and herbimycin-sensitive kinases. Phosphorylation of tyrosine residues plays an important role in signal transduction by creating docking sites for SH2 domains of signaling molecules (29). Although the CD146 molecule contains a tyrosine residue (Tyr641) in its cytoplasmic tail (10), we cannot detect any tyrosine phosphorylation of CD146 upon anti-CD146 mAb or upon NaV treatment. These results indicate that CD146 does not serve as a docking site for an SH2 adaptor/effector signaling molecule. We also show here that upon aggregation, CD146 associates with p59 fyn, a nonreceptor PTK belonging to the Src family kinases (30). p59Fyn possesses adjacent Src homology SH2 and SH3 domains involved in the binding to target proteins (31). The lack of tyrosine-phosphorylable CD146 excludes the binding by the SH2 domain of p59 fyn (32). In an other way, it is known that the SH3 domains bind to a proline-rich sequence. Although the CD146 cytoplasmic tail contains proline residues, no consensus sequence for SH3 binding site is found (33).


that CD146 cross-linking induces tyrosine phosphorylation of a protein in the range of '70 kDa detected by anti-paxillin mAb after immunoprecipitation with anti-Tyr(P) (lane 1). Association of paxillin with p125FAK was then examined. Detection of paxillin in anti-p125FAK immunoprecipitates was observed after CD146 engagement (Fig. 3C, lane 3) and was not revealed in lysates from cells stimulated with isotype-matched control mAb (Fig. 3C, lane 2). A 2-h treatment of HUVECs with 5 mM cytochalasin D before CD146 cross-linking inhibits paxillin association with p125FAK entirely (Fig. 3C, lane 4). CD 146 Clustering Results in the Association of p59 fyn with CD146—Because CD146 engagement induces the tyrosine phosphorylation of p125FAK and paxillin, we investigated whether CD146 engagement results in the recruitment of PTK(s) in the vicinity of CD146. In this regard, p125FAK possesses several binding sites for Src or Src-related kinases (26). In addition, CD146 engagement induces tyrosine phosphorylation of proteins with molecular masses ('55– 80 kDa) close to those of Src-related kinases such as p53/56lyn and p59 fyn, as well as other PTKs such as p72syk, all known to bind p125FAK. We next determine whether these PTKs are involved in CD146 signal pathway. No association between p53/56lyn or p72syk with CD146 was detected (Fig. 4, upper panel), although reprobing with anti-CD146 mAb confirmed the presence of CD146 in anti-CD146 immunoprecipitates (Fig. 4, lower panel). These results indicated that CD146 cross-linking induces the recruitment of p59 fyn kinase to CD146.

26856


Acknowledgments—We thank Anny Bottary, Andre´e Boyer and Patricia Stellmann for skillful technical assistance and Corinne Beziers La Fosse (CIML, Marseille, France) for assistance in preparing figures. We are grateful to the Biocytex company for providing 7A4 mAb and S-Endo-1 F(ab9)2 fragment. REFERENCES 1. Bardin, N., George, F., Mutin, M., Brisson, C., Horschowski, N., France`s, V., Lesaule, G., and Sampol, J. (1996) Tissue Antigens 48, 531–539 2. Bardin, N., France`s, V., Lesaule, G., Horschowski, N., George, F., and Sampol, J. (1996) Biochem. Biophys. Res. Commun. 218, 210 –216 3. Shih, I. M., Elder, D. E., Speicher, D., Johnson, J. P., and Herlyn, M. (1994) Cancer Res. 54, 2514 –2520 4. Shih, I. M., and Kurman, R. (1996) Lab. Invest. 75, 377–388 5. Pickl, W. F., Majdic, O., Fischer, G. F., Petzelbauer, P., Fae´, L., Waclavicek, M., Sto¨ckl., J., Scheinecker, C., Vidicki, T., Aschauer, H., Johnson, J. P., and

Knapp, W. (1997) J. Immunol. 158, 2107–2115 6. Shih, I. E., Hsu, M. Y., Palazzo, J. P., and Herlyn, M. (1997) Am. J. Pathol. 151, 745–751 7. Shih, I. M., Wang, T. L., and Westra, W. H. (1996) Clin. Cancer Res. 2, 569 –575 8. Lehmann, J. M., Holzmann, B., Breitbart, E. W., Schmiegelow, P., and Johnson, J. P. (1987) Cancer Res. 47, 841– 845 9. Sers, C., Kirsch, K., Rothba¨cher, U., Riethmu¨ller G., and Johnson, J. P. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8514 – 8518 10. Lehmann, J. M., Riethmu¨ller, G., and Johnson, J. P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9891–9895 11. Taira, E., Takaha, N., Taniura, H., Kim, C. H., and Miki, N. (1994) Neuron 12, 861– 872 12. Campbell, I. G., Foulkes, W. D., Senger, G., Trowsdale, J., Garin-Chesa, P., and Rettig, W. J. (1994) Cancer Res. 54, 5761–5765 13. Bowen, M., Patel, D. D., Li, X., Modrell, B., Malacko, A. R., Wang, W. C., Marquardt, H., Neubauer, M., Pesando, J. M., and Francke, U. (1995) J. Exp. Med. 181, 2213–2220 14. Laessing, U., Giordano, S., Stecher, B., Lottspeich, F., and Stuemer, C. A. O. (1996) Differentiation 56, 21–29 15. Peduzzi, J. D., Irwin, M. H., and Giesert, E. E. (1994) Brain Res. 640, 296 –307 16. Vaino, O., Dunon, D. L., Aissi, F., Dangy, J. P., McNagny, K. M., and Imhof, B. A. (1996) J. Cell Biol. 135, 1655–1668 17. Luca, M., Hunt, B., Bucana, C. D., Johnson, J. P., Fidler, I. J., and Bar-Eli, M. (1993) Melanoma Res. 3, 35– 41 18. Sers, C., Riethmu¨ller, G., and Johnson, J. P. (1994) Cancer Res. 54, 5689 –5694 19. Xie, S., Luca, M., Huang, S., Gutman, M., Reich, R., and Johnson, J. (1997) Cancer Res. 57, 2295–2303 20. Johnson, J. P., Bar-Eli, M., Jansen, B., and Markhof, E. (1997) Int. J. Cancer 73, 769 –774 21. Shih, I. E., Speicher, D., Hsu, D., Levine, E., and Herlyn, M. (1997) Cancer Res. 57, 3835–3840 22. Ming, I. E., Elder, D. E., Speicher, D., Johnson, J. P., and Herlyn, M. (1994) Cancer Res. 54, 2514 –2520 23. Lampugnani, M. G., and Dejana, E. (1997) Curr. Opin. Cell Biol. 9, 674 – 682 24. Jaffe, E., Nachman, R., Becker, C., and Minick, C. (1973) J. Clin. Invest. 52, 2745–2756 25. Donnadieu, E., Trautmann, A., Malissen, M., Trucy, J., Malissen, B., and Vivier E. (1994) J. Biol. Chem. 269, 32828 –32834 26. Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192–5196 27. Calalb, M. B., Polte, T. R., and Hanks, S. K. (1995) Mol. Cell. Biol. 15, 954 –963 28. Schlessinger, J. (1997) Cell 91, 869 – 872 29. Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., and Pawson, T. (1991) Science 252, 668 – 674 30. Kypta, R. M., Hemming, A., and Courtneidge, S. A. (1988) EMBO J. 7, 3837–3844 31. Panchamoorthy, G., Fukazawa, T., Stolz, L., Payne, G., Reedquist, K., Shoelson, S., Zhou, S., Cantley, L., Walsh, C., and Band, H. (1994) Mol. Cell. Biol. 14, 6372– 6385 32. Small, S. J., Shull, G. E., Santioni, M. J., and Akeson, R. (1987) J. Cell Biol. 105, 2335–2345 33. Pawson, T., and Scott, J. D. (1997) Science 278, 2075–2080 34. Seufferlein, T., and Rozengurt E. (1994) J. Biol. Chem. 269, 9345–9351 35. Schaller, M. D., Hildebrand, J. D., Shannon, J. D., Fox, J. W., Vines, R. R., and Parsons, J. T. (1994) Mol. Cell. Biol. 14, 1680 –1688 36. Calalb, M. B., Zhang, X., Polte, T. R., and Hanks, S. K. (1996) Biochem. Biophys. Res. Commun. 228, 662– 668 37. Batt, D. B., and Roberts, T. M. (1998) J. Biol. Chem. 273, 3408 –3414 s 38. Schaller, M. D. (1996) J. Endocrinol. 150, 1–7 39. Turner, C. E., Glenney, J. R., and Burridge, K. (1990) J. Cell Biol. 111, 1059 –1068 40. Lo, S. H., Weisberg, E., and Chen, L. B. (1994) Bioessays 16, 817– 823 41. Petch, L. A., Bockholt, S. M., Bouton, A., Parsons, J. T., and Burridge, K. (1995) J. Cell Sci. 108, 1371–1379 42. Hildebrand, J. D., Schaller, M. D., and Parsons, J. T. (1995) Mol. Biol. Cell 6, 637– 647 43. Brown, M. C., Perrotta, J. A., and Turner, C. E. (1996) J. Cell Biol. 135, 1109 –1123 44. Turner, C. E., Schaller, M. D., and Parsons, J. T. (1993) J. Cell Sci. 105, 637– 645 45. Bellis, S. L., Miller, J. T., and Turner, C. E. (1995) J. Biol. Chem. 270, 17437–17441 46. Tachibana, K., Sato, T., D’Aviro, N., and Morimoto, C. (1995) J. Exp. Med. 182, 1089 –1099 47. Illic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., and Alzawa, S. (1995) Nature 377, 539 –544 48. Cary, L. A., Chang, J. F., and Guan, J. L. (1996) J. Cell Sci. 109, 1787–1794


Therefore, the molecular basis of the p59 fyn interaction with CD146 is still unknown. Consistent with the recruitment of p59Fyn to the membrane upon CD146 engagement, we observe the tyrosine phosphorylation of two major proteins involved in the formation of focal adhesion plaques, p125FAK and paxillin. These results indicate that CD146 cross-linking induces downstream events that activate p125FAK and mediate its association with its substrates such as paxillin. Both p125FAK tyrosine phosphorylation and its association with paxillin depend on the integrity of the cytoskeleton as they are inhibited by pretreatment of cytochalasin D (34). It is well known that p125FAK possesses high affinity binding sites for members of Src family kinases, including p59 fyn, which in turn can phosphorylate other tyrosines on p125FAK (26). p59 fyn participates in the phosphorylation of Tyr at positions 397, 576, 577, and 925, present in the catalytic and COOH-terminal domains of p125FAK (27, 35, 36). These phosphorylations create multiple binding sites for substrate proteins (26, 38) including paxillin, tensin, and p130Cas (39 – 41). Paxillin is a cytoskeletal protein that localizes to sites of adhesion and binds to two sequences present in the carboxyl terminus of p125FAK (42, 43). Its association with p125FAK is thought to modulate the localization of p125FAK to focal adhesion plaques (44 – 46). Taken together, the results suggest that CD146 engagement mediates the formation of a complex among CD146, p59 fyn, p125FAK, and paxillin, which promotes focal adhesion assembly. It is tempting to speculate that CD146 engagement does not only involve an outside-in PTK pathway in HUVEC but also initiates an inside-out PTK-dependent signaling pathway. In mice, p125FAK gene inactivation impairs cell motility (47), whereas its overexpression stimulates cell migration (48). In addition, p125FAK and paxillin phosphorylations are increased by cell density (37). Preliminary results2 indicate that CD146 expression on the plasma membrane is also increased by cell density. CD146 might therefore participate in the establishment of the endothelial monolayer by initiating downstream events that promote cell proliferation and monolayer formation. Taken together, the data presented here indicate a role of CD146 in signaling. They suggest that interaction of CD146 with its still unknown ligand might lead to a similar signaling pathway.

Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125 FAK Francine Anfosso, Nathalie Bardin, Véronique Francès, Eric Vivier, Laurence Camoin-Jau, José Sampol and Françoise Dignat-George J. Biol. Chem. 1998, 273:26852-26856. doi: 10.1074/jbc.273.41.26852

Access the most updated version of this article at http://www.jbc.org/content/273/41/26852 Alerts: • When this article is cited • When a correction for this article is posted

This article cites 48 references, 32 of which can be accessed free at http://www.jbc.org/content/273/41/26852.full.html#ref-list-1


Click here to choose from all of JBC's e-mail alerts